Moderna HIV Vaccine Candidate Enters Human Trials
It marks a major medical breakthrough in 40 years, as Moderna, one of the world’s largest vaccine manufacturers, announces progress toward an HIV vaccine.
อ่านภาษาไทย
It is a major medical breakthrough in 40 years when the world's largest vaccine manufacturer, Moderna. Officially announced the progress in the production of an HIV vaccine. It is now entering Phase 1 of human testing, which is a trial in the first group of volunteers to check the safety and initial efficacy of the vaccine.
The vaccine is produced using mRNA technology, similar to the COVID-19 vaccines from both Moderna and Pfizer. Which is knowledge that has been around for more than 50 years. The advantage of mRNA is the ability to design a vaccine that, when injected into the human body. Will 'train' the immune system to create antibodies specific to a particular disease. There is no need to waste time injecting a weakened or dead virus to stimulate. The body's immune system as in the traditional vaccine model. When the vaccine is injected into the body, it will stimulate the body's immune system to create antibodies that can directly fight that type of virus. This is different from traditional vaccines that require a weakened or dead virus to be used in the immune stimulation process.
Human testing of an HIV vaccine
The ongoing human trial involves injecting the vaccine into 56 HIV-negative volunteers from the George Washington University School of Medicine. The Emory Vaccine Center Hope Clinic, the Fred Hutchinson Cancer Research Center and the University of Texas Health Science Center at San Antonio. The first 48 people will receive a first dose of the HIV vaccine. 32 of them will get a second booster dose and the remaining eight will get the booster dose only. The trial included volunteer participants from four institutions: George Washington University School of Medicine, Emory Vaccine Center Clinics, Fred Hutchinson Cancer Research Center, and the University of Texas Health Science Center. The breakthrough is the result of a collaboration between Moderna and a non-profit organization called the International AIDS Vaccine Initiative (IAVI), and CNN reports that one of the funding sources for the research is the Bill and Melinda Gates Foundation, the world's largest private foundation. HIV is a virus that causes immunodeficiency, including AIDS, which can cause low immunity and complications. Generally, when a person's body is infected with HIV, the virus attacks the immune system, weakening the body's immune system. Over the decades, humans have been trying to develop vaccines to fight HIV. Each year, a large number of people worldwide die from AIDS. Approximately 500,000-1,000,000 people. Which is a decrease from the past due to the development of antiretroviral drugs, treatment drugs, and education about prevention. However, it is still considered a high number. And vaccines are still an important solution to solve this problem in the long term. New hope lies in the development of an effective vaccine. Which could be a key solution to reduce the long-term spread of HIV and give hope to those affected by the virus. That in the future there may be more effective prevention methods. In addition, a vaccine could greatly reduce the medical and social burden. Caused by treating people living with HIV in the future. Thanks for the information from: voicetv, pptvhd36Verified references
Links and relevance to the article’s main topic were reviewed on 13 August 2026. Each source supports only the scope stated in the original document and does not replace personalised medical, legal, or service advice.
- IAVI/Moderna: HIV vaccine antigen trial Accessed 13 August 2026
- WHO: HIV and AIDS fact sheet Accessed 13 August 2026
Written and reviewed by
Love Foundation Editorial Team
Health and community-rights editorial team
Published 13 February 2022
Last updated 14 August 2026
